ID   NDB4T_ANDCR             Reviewed;          74 AA.
AC   A0A0A1I6N9;
DT   01-APR-2015, integrated into UniProtKB/Swiss-Prot.
DT   04-FEB-2015, sequence version 1.
DT   25-MAY-2022, entry version 7.
DE   RecName: Full=Antimicrobial peptide AcrAP2;
DE   Flags: Precursor;
OS   Androctonus crassicauda (Arabian fat-tailed scorpion).
OC   Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Chelicerata; Arachnida;
OC   Scorpiones; Buthida; Buthoidea; Buthidae; Androctonus.
OX   NCBI_TaxID=122909;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], MASS SPECTROMETRY, SYNTHESIS OF 23-40,
RP   FUNCTION, MUTAGENESIS OF SER-26; ASN-30; SER-33 AND SER-37, AND AMIDATION
RP   AT LYS-40.
RC   TISSUE=Venom, and Venom gland;
RX   PubMed=25332684; DOI=10.7150/ijbs.9859;
RA   Du Q., Hou X., Ge L., Li R., Zhou M., Wang H., Wang L., Wei M., Chen T.,
RA   Shaw C.;
RT   "Cationicity-enhanced analogues of the antimicrobial peptides, AcrAP1 and
RT   AcrAP2, from the venom of the scorpion, Androctonus crassicauda, display
RT   potent growth modulation effects on human cancer cell lines.";
RL   Int. J. Biol. Sci. 10:1097-1107(2014).
CC   -!- FUNCTION: Has antimicrobial activity against the Gram-positive bacteria
CC       S.aureus (MIC=8 uM) and the yeast C.albicans (MIC=16 uM). Causes
CC       hemolysis on horse erythrocytes (64 uM for 100% hemolysis). Minimum
CC       bactericidal concentrations have also been tested against S.aureus and
CC       is four-fold higher (MBC=32 uM). {ECO:0000269|PubMed:25332684}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:25332684}. Target
CC       cell membrane {ECO:0000250}. Note=Forms a helical membrane channel in
CC       the prey. {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed by the venom gland. {ECO:0000305}.
CC   -!- MASS SPECTROMETRY: Mass=1937.39; Method=Electrospray;
CC       Evidence={ECO:0000269|PubMed:25332684};
CC   -!- MISCELLANEOUS: Does not show antimicrobial activity against the Gram-
CC       negative bacteria E.coli (MIC>250 uM). Does not show effect on four
CC       different human cancer cell lines. {ECO:0000269|PubMed:25332684}.
CC   -!- SIMILARITY: Belongs to the non-disulfide-bridged peptide (NDBP)
CC       superfamily. Short antimicrobial peptide (group 4) family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; HG939519; CDN67528.1; -; mRNA.
DR   AlphaFoldDB; A0A0A1I6N9; -.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-KW.
DR   GO; GO:0042742; P:defense response to bacterium; IEA:UniProtKB-KW.
DR   GO; GO:0050832; P:defense response to fungus; IEA:UniProtKB-KW.
DR   GO; GO:0031640; P:killing of cells of another organism; IEA:UniProtKB-KW.
PE   1: Evidence at protein level;
KW   Amidation; Antibiotic; Antimicrobial; Cleavage on pair of basic residues;
KW   Fungicide; Membrane; Secreted; Signal; Target cell membrane;
KW   Target membrane.
FT   SIGNAL          1..22
FT                   /evidence="ECO:0000269|PubMed:25332684"
FT   PEPTIDE         23..40
FT                   /note="Antimicrobial peptide AcrAP2"
FT                   /id="PRO_0000432594"
FT   PROPEP          46..74
FT                   /evidence="ECO:0000269|PubMed:25332684"
FT                   /id="PRO_0000432595"
FT   MOD_RES         40
FT                   /note="Lysine amide"
FT                   /evidence="ECO:0000269|PubMed:25332684"
FT   MUTAGEN         26
FT                   /note="S->K: Shows important increase in antimicrobial
FT                   activity against E.coli (MIC=8 uM) and slight increase
FT                   against S.aureus (MIC=4 uM) and C.albicans (MIC=4 uM), as
FT                   well as slight increase in hemolytic activity (32 uM for
FT                   100% hemolysis). Also shows anti-proliferative effects on
FT                   four cancer cell lines; when associated with K-30; K-33 and
FT                   K-37."
FT                   /evidence="ECO:0000269|PubMed:25332684"
FT   MUTAGEN         30
FT                   /note="N->K: Shows important increase in antimicrobial
FT                   activity against E.coli (MIC=8 uM) and slight increase
FT                   against S.aureus (MIC=4 uM) and C.albicans (MIC=4 uM), as
FT                   well as slight increase in hemolytic activity (32 uM for
FT                   100% hemolysis). Also shows anti-proliferative effects on
FT                   four cancer cell lines; when associated with K-26; K-33 and
FT                   K-37."
FT                   /evidence="ECO:0000269|PubMed:25332684"
FT   MUTAGEN         33
FT                   /note="S->K: Shows important increase in antimicrobial
FT                   activity against E.coli (MIC=8 uM) and slight increase
FT                   against S.aureus (MIC=4 uM) and C.albicans (MIC=4 uM), as
FT                   well as slight increase in hemolytic activity (32 uM for
FT                   100% hemolysis). Also shows anti-proliferative effects on
FT                   four cancer cell lines; when associated with K-26; K-30 and
FT                   K-37."
FT                   /evidence="ECO:0000269|PubMed:25332684"
FT   MUTAGEN         37
FT                   /note="S->K: Shows important increase in antimicrobial
FT                   activity against E.coli (MIC=8 uM) and slight increase
FT                   against S.aureus (MIC=4 uM) and C.albicans (MIC=4 uM), as
FT                   well as slight increase in hemolytic activity (32 uM for
FT                   100% hemolysis). Also shows anti-proliferative effects on
FT                   four cancer cell lines; when associated with K-26; K-30 and
FT                   K-33."
FT                   /evidence="ECO:0000269|PubMed:25332684"
SQ   SEQUENCE   74 AA;  8655 MW;  8938BCBD2F67D45C CRC64;
     MEIKYLLTVF LVLLIVSDHC QAFLFSLIPN AISGLLSAFK GRRKRNLDGQ IDRFRNFRKR
     DAELEELLSK LPIY